Proven non-carriers in BRCA families have an earlier age of onset of breast cancer

European Journal of Cancer

Volumn 49, Issue 9, 2013, Pages 2101-2106

  Vos, Janet R ^a   De Bock, Geertruida H ^a   Teixeira, Natalia ^a   Van Der Kolk, Dorina M ^a   Jansen, Liesbeth ^a   Mourits, Marian J E ^a   Oosterwijk, Jan C ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

BRCA; Breast cancer; Non carrier; Ovarian cancer; Risk assessment

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ADULT; ARTICLE; BREAST CANCER; CANCER RISK; COHORT ANALYSIS; FEMALE; GENE MUTATION; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; ONSET AGE; OVARY CANCER; POPULATION; PRIORITY JOURNAL; STANDARDIZED INCIDENCE RATIO; TUMOR SUPPRESSOR GENE;

ADULT; AGE OF ONSET; BREAST NEOPLASMS; COHORT STUDIES; FEMALE; GENES, BRCA1; GENES, BRCA2; HETEROZYGOTE; HUMANS; MIDDLE AGED; MUTATION; OVARIAN NEOPLASMS; PEDIGREE; RISK FACTORS;

EID: 84877711552     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2013.02.018     Document Type: Article

References (31)

1. S. Chen, and G. Parmigiani Meta-analysis of BRCA1 and BRCA2 penetrance J Clin Oncol 25 2007 1329 1333
2. A. Antoniou, P.D. Pharoah, and S. Narod Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies Am J Hum Genet 72 2003 1117 1130
3. D.M. van der Kolk, G.H. de Bock, and B.K. Leegte Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age Breast Cancer Res Treat 124 2010 643 651
4. D.G. Evans, A. Shenton, E. Woodward, F. Lalloo, A. Howell, and E.R. Maher Penetrance estimates for BRCA1 and BRCA2 based on genetic testing in a clinical cancer genetics service setting: risks of breast/ovarian cancer quoted should reflect the cancer burden in the family BMC Cancer 8 2008 155
5. D. Ford, D.F. Easton, and M. Stratton Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families: the breast cancer linkage consortium Am J Hum Genet 62 1998 676 689
6. D.F. Easton, D. Ford, and D.T. Bishop Breast and ovarian cancer incidence in BRCA1-mutation carriers: breast cancer linkage consortium Am J Hum Genet 56 1995 265 271
7. Comprehensive Cancer Centre the Netherlands. Mammacarcinoma (national guideline, version 2.0). Oncolines, cancer clinical practice guidelines. Cited 05/01/2012. Available from: http://www.oncoline.nl/mammacarcinoom.
8. S.M. Domchek, M.M. Gaudet, and J.E. Stopfer Breast cancer risks in individuals testing negative for a known family mutation in BRCA1 or BRCA2 Breast Cancer Res Treat 119 2010 409 414
9. L.A. Korde, C.M. Mueller, and J.T. Loud No evidence of excess breast cancer risk among mutation-negative women from BRCA mutation-positive families Breast Cancer Res Treat 125 2011 169 173
10. A.W. Kurian, G.D. Gong, and E.M. John Breast cancer risk for noncarriers of family-specific BRCA1 and BRCA2 mutations: findings from the breast cancer family registry J Clin Oncol 29 2011 4505 4509
11. S.L. Harvey, R.L. Milne, and S.A. McLachlan Prospective study of breast cancer risk for mutation negative women from BRCA1 or BRCA2 mutation positive families Breast Cancer Res Treat 130 2011 1057 1061
12. D.G. Evans, and A. Howell Breast cancer risk for noncarriers of family-specific BRCA1 and BRCA2 mutations: more trouble with phenocopies J Clin Oncol 30 2012 1142 1143 author reply 1143-4
13. H.A. Katki, M.H. Gail, and M.H. Greene Breast-cancer risk in BRCA-mutation-negative women from BRCA-mutation-positive families Lancet Oncol 8 2007 1042 1043
14. A. Smith, A. Moran, and M.C. Boyd Phenocopies in BRCA1 and BRCA2 families: evidence for modifier genes and implications for screening J Med Genet 44 2007 10 15
15. E. Rowan, A. Poll, and S.A. Narod A prospective study of breast cancer risk in relatives of BRCA1/BRCA2 mutation carriers J Med Genet 44 2007 e89 author reply e88
16. J. Gronwald, C. Cybulski, J. Lubinski, and S.A. Narod Phenocopies in breast cancer 1 (BRCA1) families: implications for genetic counselling J Med Genet 44 2007 e76
17. A.H. van der Hout, A.M. van den Ouweland, and R.B. van der Luijt A DGGE system for comprehensive mutation screening of BRCA1 and BRCA2: application in a Dutch cancer clinic setting Hum Mutat 27 2006 654 666
18. G.H. de Bock, J.W. Hesselink, and C. Roorda Model of care for women at increased risk of breast and ovarian cancer Maturitas 71 2011 3 5
19. Comprehensive Cancer Centre the Netherlands. Dutch cancer figures. Cited 05/08/2012. Available from: http://www.cijfersoverkanker.nl/.
20. Curado MP, Edwards B, Shin HR, et al., editors. Cancer incidence in five continents, vol. IX. IARC Scientific Publications No. 160, Lyon, IACR.
21. M. Dorval, C. Nogues, and P. Berthet Breast and ovarian cancer screening of non-carriers from BRCA1/2 mutation-positive families: 2-year follow-up of cohorts from France and Quebec Eur J Hum Genet 19 2011 494 499
22. T.M. Allweis, M. Sagi, and T. Peretz Sporadic breast cancer among relatives of BRCA mutation carriers Genet Med 7 2005 655 656
23. D.R. Barnes, and A.C. Antoniou Unravelling modifiers of breast and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: update on genetic modifiers J Intern Med 271 2012 331 343
24. A.C. Antoniou, K.B. Kuchenbaecker, and P. Soucy Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers Breast Cancer Res 14 2012 R33
25. H.J. Murff, D.R. Spigel, and S. Syngal Does this patient have a family history of cancer? An evidence-based analysis of the accuracy of family cancer history JAMA 292 2004 1480 1489
26. R.H. Sijmons, A.E. Boonstra, and J. Reefhuis Accuracy of family history of cancer: clinical genetic implications Eur J Hum Genet 8 2000 181 186
27. D. Goldgar, V. Venne, T. Conner, and S. Buys BRCA phenocopies or ascertainment bias? J Med Genet 44 2007 e86 author reply e88
28. P. Sasieni Phenocopies in families seen by cancer geneticists J Med Genet 44 2007 e82
29. N.T. van Ravensteyn, D.L. Miglioretti, and N.K. Stout Tipping the balance of benefits and harms favor screening mammography starting at age 40 years. A comparative modeling study of risk Ann Intern Med 156 2012 609 617
30. H.M. Zonderland, M.K. Tuut, and G.J. den Heeten Revised practice guideline 'screening and diagnosis of breast cancer' Ned Tijdschr Geneeskd 152 2008 2336 2339
31. K. Moser, S. Sellars, and M. Wheaton Extending the age range for breast screening in England: pilot study to assess the feasibility and acceptability of randomization J Med Screen 18 2011 96 102